Sugar Rush Souring: Analyst Downgrades Hershey As 2024 Competition Turns Bitter

RBC Capital Markets analyst Nik Modi downgraded The Hershey Co (NYSE: HSY) to Sector Perform from Outperform at a 

RBC Capital Markets analyst Nik Modi downgraded The Hershey Co (NYSE:HSY) to Sector Perform from Outperform at a lowered price target of $213 from $239. 

The analysts’ re-rating reflects the expected intense competitive landscape in 2024 across HSY’s chocolate/confection categories in the U.S., as probably Mars and Ferraro/Ferrera will likely elevate their marketing, promotional spending, and innovation in the upcoming year.

The analyst notes that in 2023, HSY’s shares have come under pressure due to the overall underperformance of the packaged food space (GLP-1 concerns, higher interest rates, and weakening macros pressuring volume) and share erosion.

Modi expects Hershey’s efforts to regain volume growth and market share to be impacted by these macro factors, making it difficult for the company to realize the net pricing required to fully offset rising sugar/cocoa costs.

Consequently, the analyst cuts estimates for revenue to $11.239 billion (from $11.249 billion prior) for FY23 and $11.519 billion (from $11.582 billion earlier) for FY24.

RelatedHershey Analysts Cut Their Forecasts After Q3 Results

Also, EPS estimates are reduced to $9.53 (from 9.54) for FY23 and $10.10 (from $10.23) for FY24.

Also ReadChocolate Maker Hershey Sweetens Brand Investment Eyeing Fast Start To 2024; Beats On Q3

Price Action: HSY shares are trading lower by 1.27% at $190.62 on the last check Tuesday.

Total
0
Shares
Related Posts
Read More

CBD Helps With This Rare Blistering Skin Disorder, New Study From Avicanna Shows Promising Results In Epidermolysis Bullosa Treatment

There is no cure for a rare blistering skin disorder called Epidermolysis Bullosa (EB). But, treatments to help alleviate and control the symptoms do exist. The growing body of research suggests cannabinoid-based medicines help ease pain and pruritus in those with a disorder while improving wound healing.The latest scientifically prove healing power of cannabis was Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products.

AVCNF